Similar articles for PMID: 36773969

Year	Number of Results
1967	1
1977	1
1984	2
1985	1
1986	1
1989	1
1990	3
1991	1
1992	1
1993	2
1994	1
1995	1
1996	5
1999	1
2000	1
2001	4
2002	2
2003	1
2004	3
2005	2
2006	5
2007	2
2008	3
2009	7
2010	8
2012	8
2013	7
2014	5
2015	3
2016	4
2017	3
2018	6
2019	4
2020	1
2021	3
2023	1
2024	0

1

WHO and Gilead Sciences extend collaborative agreement to enhance access to treatment for visceral leishmaniasis.

[No authors listed] [No authors listed] Saudi Med J. 2023 Feb;44(2):227-228. Saudi Med J. 2023. PMID: 36773969 Free PMC article. No abstract available.

2

Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study.

Mondal D, Alvar J, Hasnain MG, Hossain MS, Ghosh D, Huda MM, Nabi SG, Sundar S, Matlashewski G, Arana B. Mondal D, et al. Lancet Glob Health. 2014 Jan;2(1):e51-7. doi: 10.1016/S2214-109X(13)70118-9. Epub 2013 Dec 5. Lancet Glob Health. 2014. PMID: 25104636 Free article.

3

Development status of miltefosine as first oral drug in visceral and cutaneous leishmaniasis.

Fischer C, Voss A, Engel J. Fischer C, et al. Med Microbiol Immunol. 2001 Nov;190(1-2):85-7. doi: 10.1007/s004300100087. Med Microbiol Immunol. 2001. PMID: 11770118 Review.

4

Visceral leishmaniasis treatment in the Indian subcontinent: how to reach the most vulnerable.

Picado A, Rijal S, Sundar S, Boelaert M. Picado A, et al. Expert Rev Anti Infect Ther. 2012 Aug;10(8):839-41. doi: 10.1586/eri.12.71. Expert Rev Anti Infect Ther. 2012. PMID: 23030320 No abstract available.

5

Treatment of visceral leishmaniasis.

Sundar S, Rai M. Sundar S, et al. Expert Opin Pharmacother. 2005 Dec;6(16):2821-9. doi: 10.1517/14656566.6.16.2821. Expert Opin Pharmacother. 2005. PMID: 16318433 Review.

6

Elimination of visceral leishmaniasis on the Indian subcontinent.

Singh OP, Hasker E, Boelaert M, Sundar S. Singh OP, et al. Lancet Infect Dis. 2016 Dec;16(12):e304-e309. doi: 10.1016/S1473-3099(16)30140-2. Epub 2016 Sep 28. Lancet Infect Dis. 2016. PMID: 27692643 Free PMC article. Review.

7

Treatment of visceral leishmaniasis: a review of current treatment practices.

Marty P, Rosenthal E. Marty P, et al. Expert Opin Pharmacother. 2002 Aug;3(8):1101-8. doi: 10.1517/14656566.3.8.1101. Expert Opin Pharmacother. 2002. PMID: 12150689 Review.

8

Visceral leishmaniasis in Somalia: A review of epidemiology and access to care.

Sunyoto T, Potet J, Boelaert M. Sunyoto T, et al. PLoS Negl Trop Dis. 2017 Mar 9;11(3):e0005231. doi: 10.1371/journal.pntd.0005231. eCollection 2017 Mar. PLoS Negl Trop Dis. 2017. PMID: 28278151 Free PMC article. Review.

9

Coping with visceral leishmaniasis in Turkey.

Cakan HS, Iscan MY, Oz V, Aslan M, Karayel TM, Cakir I, Uner HB. Cakan HS, et al. Saudi Med J. 2009 Nov;30(11):1480-2. Saudi Med J. 2009. PMID: 19882066 No abstract available.

10

India makes good progress in combating kala-azar.

Cousins S. Cousins S. Lancet. 2015 May 2;385(9979):1716. doi: 10.1016/S0140-6736(15)60877-7. Lancet. 2015. PMID: 25943925 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year